EXEL - Exelixis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.50
-0.08 (-0.39%)
At close: 4:00PM EDT

20.50 0.00 (0.00%)
After hours: 5:36PM EDT

Stock chart is not supported by your current browser
Previous Close20.58
Open20.50
Bid20.21 x 800
Ask20.68 x 3100
Day's Range20.21 - 20.74
52 Week Range18.03 - 32.50
Volume1,862,197
Avg. Volume3,851,522
Market Cap6.086B
Beta2.23
PE Ratio (TTM)41.58
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx
    Zacksyesterday

    Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx

    Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool5 days ago

    3 Top Biotech Stocks to Buy Right Now

    Want to invest in this promising industry but don't know where to start? Here are three stocks that can get the ball rolling.

  • Exelixis Is Focused on Management of the Cabozantinib Franchise
    Market Realist6 days ago

    Exelixis Is Focused on Management of the Cabozantinib Franchise

    Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.

  • Label Expansion May Boost Cabometyx’s Revenue in 2018
    Market Realist6 days ago

    Label Expansion May Boost Cabometyx’s Revenue in 2018

    On January 16, Exelixis (EXEL) and Ipsen announced positive results from the CELESTIAL Phase 3 trial highlighting the statistically significant and clinically meaningful improvement in the trial’s primary end point of overall survival due to cabozantinib therapy compared to a placebo in second-line and third-line hepatocellular carcinoma (or HCC) patients.

  • Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018
    Market Realist6 days ago

    Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018

    In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume driven by both new patient starts and a robust rise in the total number of patients on the therapy. According to a report, ~295,000 people across the world are diagnosed with kidney cancer every year, while 134,000 kidney cancer patients die every year. According to the American Cancer Society’s Cancer Facts & Figures 2018, the annual incidence of kidney cancer in the United States is ~65,000, while the annual death toll of the disease is 15,000. Another report estimates that almost 70%–75% of renal cell cancer (or RCC) patients suffer from clear cell RCC.

  • Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space
    Market Realist7 days ago

    Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space

    Exelixis (EXEL) aims to position Cabometyx as the preferred tyrosine-kinase inhibitor (or TKI) in the renal cell carcinoma (or RCC) segment. At the end of 2017, Cabometyx had managed to acquire a 42% share of the second-line and new patient advanced RCC market, higher than its 39% market share at the end of the third quarter of 2017. Cabometyx demonstrated superiority over Pfizer’s (PFE) Sutent as a first-line RCC therapy in its Phase 2 CABOSUN trial in terms of progression-free survival, which has helped boost physicians’ confidence in Cabometyx.

  • Exelixis Is Expected to Report a Robust Revenue Rise in 2018
    Market Realist7 days ago

    Exelixis Is Expected to Report a Robust Revenue Rise in 2018

    The company reported net income of close to $115.9 million in the quarter, a YoY rise of ~594% and a sequential rise of 201%. Exelixis reported diluted GAAP (generally accepted accounting principles) EPS (earnings per share) of close to $0.37, a YoY rise of ~585% and a sequential rise of 201%. Analysts expect Exelixis to report revenue of close to $723 million in 2018, a YoY rise of ~59.8%.

  • Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer
    Zacks7 days ago

    Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer

    European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.

  • Why Exelixis Stock Fell Last Week
    Market Realist7 days ago

    Why Exelixis Stock Fell Last Week

    On May 11, Exelixis’s (EXEL) closing price was $19.55, almost 12.9% lower than its closing price on May 4. This fall was mainly attributable to unfavorable results released from its Phase 3 IMblaze370 study comparing a combination regimen of Cotellic (cobimetinib) with Roche Holdings’ (RHHBY) Tecentriq (atezolizumab) compared to Bayer’s Stivarga in locally advanced or metastatic colorectal cancer indications. Exelixis and Roche Holdings’ investigational combination regimen failed to demonstrate a statistically significant improvement in the primary end point of overall survival compared to Stivarga in difficult-to-treat patients who had witnessed disease progression or had been unable to tolerate at least two chemotherapy treatments.

  • Benzinga7 days ago

    Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 16) Abaxis Inc (NASDAQ: ABAX ) (announced a deal to be bought ...

  • Are Options Traders Betting on a Big Move in Exelixis (EXEL) Stock?
    Zacks8 days ago

    Are Options Traders Betting on a Big Move in Exelixis (EXEL) Stock?

    Investors in Exelixis (EXEL) need to pay close attention to the stock based on moves in the options market lately.

  • Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.
    Zacks13 days ago

    Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.

    Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.

  • Lenvima Is Expected to Boost Merck’s Oncology Portfolio in 2018
    Market Realist13 days ago

    Lenvima Is Expected to Boost Merck’s Oncology Portfolio in 2018

    On March 7, Merck (MRK) announced that it had entered a collaboration with Eisai for the co-development and co-commercialization of the latter’s oral protein tyrosine kinase inhibitor, Lenvima, as a monotherapy and in combination regimens with Keytruda in multiple oncology indications. Lenvima monotherapy is currently approved in more than 50 countries as treatment for progressive differentiated thyroid cancer patients that witness disease progression despite being treated with radioactive iodine therapy. Lenvima in combination with Novartis’s (NVS) Afinitor is approved in more than 40 countries for the second-line renal cell carcinoma indication.

  • Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day
    Zacks13 days ago

    Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day

    Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day

  • Array BioPharma (ARRY) in Focus: Stock Moves 5.5% Higher
    Zacks13 days ago

    Array BioPharma (ARRY) in Focus: Stock Moves 5.5% Higher

    Array BioPharma (ARRY) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.

  • Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
    Zacks13 days ago

    Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter

    Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter

  • 3 Healthcare Stocks Growing Over 100%
    Motley Fool13 days ago

    3 Healthcare Stocks Growing Over 100%

    Massive sales growth at these companies could make them the perfect stocks to add to your portfolio.

  • Bull of the Day: Exelixis (EXEL)
    Zacks13 days ago

    Bull of the Day: Exelixis (EXEL)

    Bull of the Day: Exelixis (EXEL)

  • This Biotech Stock Crashed On Colon Cancer Flop With Roche
    Investor's Business Daily14 days ago

    This Biotech Stock Crashed On Colon Cancer Flop With Roche

    Exelixis stock tanked Thursday after a regimen using its drug and another from Roche failed in a late-stage study of hard-to-treat colon cancer patients.

  • Why Booking Holdings, Exelixis, and L Brands Slumped Today
    Motley Fool14 days ago

    Why Booking Holdings, Exelixis, and L Brands Slumped Today

    Find out how earnings hurt some of these companies despite a strong market day.

  • Hospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings
    Zacks14 days ago

    Hospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings

    Mallinckrodt's earnings and sales beat in the first quarter boosted investor sentiment as hospital products sales revived.

  • Why Exelixis Dropped Today
    Motley Fool14 days ago

    Why Exelixis Dropped Today

    The company announced a disappointing clinical trial failure, which fortunately wasn't for its top-selling drug.

  • 5 Winning Stocks With Superb Efficiency Level
    Zacks14 days ago

    5 Winning Stocks With Superb Efficiency Level

    A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

  • Analysts’ Recommendations for Regeneron Pharmaceuticals in May
    Market Realist14 days ago

    Analysts’ Recommendations for Regeneron Pharmaceuticals in May

    In April 2018, the FDA accepted for priority review Regeneron Pharmaceuticals (REGN) and Sanofi’s (SNY) Biologics License Application (or BLA) for cemiplimab for the treatment of individuals with metastatic CSCC (cutaneous squamous cell carcinoma) or individuals with locally advanced CSCC who cannot be treated with surgery. In September 2017, the FDA granted cemiplimab Breakthrough Therapy designation status for the treatment of metastatic CSCC. The FDA provided a Prescription Drug User Fee Act action date of October 28, 2018.

  • Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss
    Zacks15 days ago

    Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss

    Prothena's (PRTA) wider-than-expected loss in the first quarter was disappointing. Sales also missed estimates by a huge margin.